From Ingenix Epidemiology, and the Safety Evaluation and Epidemiology, Pfizer Inc.; and the Pfizer Pharmaceuticals Group Medical, Pfizer Inc.
Severe Vascular Events in Migraine Patients
Article first published online: 18 JUN 2004
Headache: The Journal of Head and Face Pain
Volume 44, Issue 7, pages 642–651, July 2004
How to Cite
Velentgas, P., Cole, J. A., Mo, J., Sikes, C. R. and Walker, A. M. (2004), Severe Vascular Events in Migraine Patients. Headache: The Journal of Head and Face Pain, 44: 642–651. doi: 10.1111/j.1526-4610.2004.04122.x
- Issue published online: 18 JUN 2004
- Article first published online: 18 JUN 2004
- Accepted for publication March 2, 2004.
- myocardial infarction;
Objective.—To estimate rates of vascular events in relation to dispensing of triptans and ergot alkaloids among migraineurs, and to compare these rates with those of nonmigraineurs.
Context.—It has been speculated that the use of triptans or ergot alkaloid drugs might increase risk of ischemic events through vasoconstriction.
Design.—A retrospective cohort study of 130,411 migraineurs and 130,411 age-, sex-, and health plan-matched nonmigraineurs who were members of UnitedHealthcare during 1995 through 1999. The data source for this study was Ingenix's research database containing pharmacy and medical claims for UnitedHealthcare members, and the National Death Index.
Main Outcome Measures.—Incidence of cardiovascular and cerebrovascular events and mortality.
Results.—Migraineurs and nonmigraineurs had identical rates of myocardial infarction: 1.4 per 1000 person-years. Migraineurs were 67% more likely to suffer a stroke than nonmigraineurs (adjusted relative risk [RR] 1.67, 95% confidence interval [CI] 1.31–2.13), and had higher rates of unstable angina and transient ischemic attacks. There was no increase in risk of myocardial infarction with current (adjusted RR 0.80, 95% CI 0.58–1.11) or recent (adjusted RR 1.15, 95% CI 0.71–1.87) triptan use. Neither current (adjusted RR 0.90, 95% CI 0.64–1.26) nor recent (adjusted RR 0.84, 95% CI 0.46–1.55) triptan use was associated with risk of stroke. Current users of ergot alkaloids were somewhat more likely to have a stroke than other migraineurs (adjusted RR 1.49, 95% CI 0.93–2.41), but there was no dose-response relationship.
Conclusions.—Use of triptans is not associated with increased risk of any ischemic events, including myocardial infarction and stroke, or mortality. Consistent with previous studies, migraineurs in general have an elevated risk of stroke, but not myocardial infarction, compared with nonmigraineurs.